Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2012. The report details a specific corporate action regarding share repurchases executed on July 26, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,438 pence per share; lowest price paid was 1,416.5 pence per share.
- Treasury Holdings (Settled): 478,307,927 shares (8.75% of total issued share capital).
- Treasury Holdings (Including Unsettled): 479,907,927 shares (9.62% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,991,145,137 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,600,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 9.62% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (479,907,927) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,991,145,137 shares in issue) for disclosure threshold assessments under Financial Services Authority rules.
- Review the price paid per share (1,416.5 to 1,438 pence) against market trading data for July 26, 2012.